AU2015317877A1 - Methods and compositions for treating psychotic disorders - Google Patents

Methods and compositions for treating psychotic disorders Download PDF

Info

Publication number
AU2015317877A1
AU2015317877A1 AU2015317877A AU2015317877A AU2015317877A1 AU 2015317877 A1 AU2015317877 A1 AU 2015317877A1 AU 2015317877 A AU2015317877 A AU 2015317877A AU 2015317877 A AU2015317877 A AU 2015317877A AU 2015317877 A1 AU2015317877 A1 AU 2015317877A1
Authority
AU
Australia
Prior art keywords
glutathione
cysteine
nvhl
rats
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015317877A
Other languages
English (en)
Inventor
Jonathan Kil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sound Pharmaceuticals Inc
Original Assignee
Sound Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Inc filed Critical Sound Pharmaceuticals Inc
Publication of AU2015317877A1 publication Critical patent/AU2015317877A1/en
Priority to AU2021200583A priority Critical patent/AU2021200583A1/en
Priority to AU2023200727A priority patent/AU2023200727A1/en
Priority to AU2025201645A priority patent/AU2025201645A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015317877A 2014-09-15 2015-09-15 Methods and compositions for treating psychotic disorders Abandoned AU2015317877A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2021200583A AU2021200583A1 (en) 2014-09-15 2021-01-29 Methods and compositions for treating psychotic disorders
AU2023200727A AU2023200727A1 (en) 2014-09-15 2023-02-10 Methods and compositions for treating psychotic disorders
AU2025201645A AU2025201645A1 (en) 2014-09-15 2025-03-06 Methods and compositions for treating psychotic disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050635P 2014-09-15 2014-09-15
US62/050,635 2014-09-15
PCT/US2015/050255 WO2016044314A1 (en) 2014-09-15 2015-09-15 Methods and compositions for treating psychotic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200583A Division AU2021200583A1 (en) 2014-09-15 2021-01-29 Methods and compositions for treating psychotic disorders

Publications (1)

Publication Number Publication Date
AU2015317877A1 true AU2015317877A1 (en) 2017-05-04

Family

ID=55533760

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015317877A Abandoned AU2015317877A1 (en) 2014-09-15 2015-09-15 Methods and compositions for treating psychotic disorders
AU2021200583A Abandoned AU2021200583A1 (en) 2014-09-15 2021-01-29 Methods and compositions for treating psychotic disorders
AU2023200727A Abandoned AU2023200727A1 (en) 2014-09-15 2023-02-10 Methods and compositions for treating psychotic disorders
AU2025201645A Pending AU2025201645A1 (en) 2014-09-15 2025-03-06 Methods and compositions for treating psychotic disorders

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2021200583A Abandoned AU2021200583A1 (en) 2014-09-15 2021-01-29 Methods and compositions for treating psychotic disorders
AU2023200727A Abandoned AU2023200727A1 (en) 2014-09-15 2023-02-10 Methods and compositions for treating psychotic disorders
AU2025201645A Pending AU2025201645A1 (en) 2014-09-15 2025-03-06 Methods and compositions for treating psychotic disorders

Country Status (7)

Country Link
US (3) US20170246148A1 (enExample)
EP (1) EP3194027A4 (enExample)
JP (3) JP2017534673A (enExample)
KR (2) KR20230107890A (enExample)
AU (4) AU2015317877A1 (enExample)
CA (1) CA2961380A1 (enExample)
WO (1) WO2016044314A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6308134B2 (ja) * 2012-12-27 2018-04-11 ソニー株式会社 細胞分析システム、細胞分析プログラム及び細胞分析方法
EP3037514B1 (en) 2013-11-08 2018-12-26 Sony Corporation Cell analysis system, cell analysis program, and cell analysis method
KR102474830B1 (ko) * 2016-05-18 2022-12-06 사운드 파마슈티칼스 인코퍼레이티드 중이염의 치료
CN107362144B (zh) * 2017-08-03 2020-04-17 华侨大学 一种鲁拉西酮脑靶向脂质体注射剂及其制备方法
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
CN111432813B (zh) * 2017-11-14 2024-01-09 爱思开生物制药株式会社 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物
AU2020448022B2 (en) * 2020-05-09 2024-05-09 Shenzhen Profound View Pharmaceutical Technology Co., Ltd. Treatment of adverse effects caused by atypical antipsychotics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2650204A1 (en) * 1996-12-31 1998-07-09 Harry B. Demopoulos Pharmaceutical preparations of glutathione and methods of administration thereof
JP4684553B2 (ja) * 2001-09-27 2011-05-18 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 生理学的過程の調節およびこれに有用な薬剤
KR20080028357A (ko) * 2005-04-21 2008-03-31 글렌 에이. 골드스타인 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드)
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
ZA200902203B (en) * 2006-10-23 2010-08-25 Mental Health Res Inst Of Vict Combination therapy
CA2842106A1 (en) * 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs

Also Published As

Publication number Publication date
AU2023200727A1 (en) 2023-03-09
AU2025201645A1 (en) 2025-03-27
US20210379017A1 (en) 2021-12-09
EP3194027A4 (en) 2018-04-18
JP2021181473A (ja) 2021-11-25
JP2017534673A (ja) 2017-11-24
US20170246148A1 (en) 2017-08-31
CA2961380A1 (en) 2016-03-24
JP2023169413A (ja) 2023-11-29
KR20230107890A (ko) 2023-07-18
KR20170066432A (ko) 2017-06-14
AU2021200583A1 (en) 2021-03-04
EP3194027A1 (en) 2017-07-26
US20240050409A1 (en) 2024-02-15
WO2016044314A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
US20240050409A1 (en) Methods and Compositions for Treating Psychotic Disorders
Dong-Chen et al. Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Lu et al. Cellular mitophagy: mechanism, roles in diseases and small molecule pharmacological regulation
US10966962B2 (en) Method for treating neurodegenerative diseases
ES2750728T3 (es) Uso de cannabinoides en combinación con Aripriprazol
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
BRPI0611322A2 (pt) métodos e composicões para controlar distúrbios psicóticos
EP3297619B1 (en) Therapeutic uses of l-4-chlorokynurenine
Kim et al. Neuroprotective effects of a protein tyrosine phosphatase inhibitor against hippocampal excitotoxic injury
Saleh et al. Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors
TR201908928T4 (tr) Parkinsoniyan sendromları olan nörodejeneratif hastalıkları tedavi etmek için bümetanid.
Li et al. Intravitreal delivery of melatonin is protective against the photoreceptor loss in mice: a potential therapeutic strategy for degenerative retinopathy
CN101316584A (zh) 用于预防及治疗由血管通透性亢进引起的眼病的医药
WO2013017136A1 (en) Treatment of cognitive impairment
TW201808294A (zh) 用於預防或治療神經退化性疾病之醫藥組成物
JP5978472B2 (ja) 耳鳴患者の治療用の薬剤
JP2025507361A (ja) 網膜酸化的疾患の治療に対する患者の反応をモニタリングする方法
Falah The role of the cdk5 pathway and NMDA receptor phosphorylation in neurodegeneration in hippocampal sclerosis
Hyppolito et al. Cisplatin ototoxicity and otoprotetor to cilliated cells by ginkgo biloba extract: anatomic and eletrophisiologic study
Hettinger The Regulation of Extracellular Amyloid-β Levels by Ionotropic Glutamatergic Transmission in an Alzheimer's Disease Mouse Model
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted